RecruitingNot ApplicableNCT07170267

Transversalis Fascia Plane Block Versus Intrathecal Dexmedetomidine in Patients Undergoing Cesarean Section

Analgesic Efficacy of Transversalis Fascia Plane Block Versus Intrathecal Dexmedetomidine in Patients Undergoing Cesarean Section: A Randomized Controlled Trial


Sponsor

Tanta University

Enrollment

50 participants

Start Date

Sep 13, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This study aims to compare the analgesic efficacy of the transversalis fascia plane (TFP) block and intrathecal dexmedetomidine in patients undergoing cesarean section (CS).


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 40 Years

Inclusion Criteria3

  • Age from 18 to 40 years.
  • American Society of Anesthesiology (ASA) physical status II.
  • Women undergoing cesarean section under spinal anesthesia.

Exclusion Criteria11

  • Contraindication to spinal anesthesia.
  • Women with body mass index \>40 kg/m2.
  • Pregnancy-induced hypertension
  • Local infection at the site of injection.
  • Known cardiovascular disease
  • Coagulation abnormality.
  • History of chronic pain.
  • Abuse of drugs or alcohol.
  • History of allergies to any study medications.
  • Seizure disorders.
  • Any pregnancy complications requiring conversion to general anesthesia.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERTransversalis fascia plane block

Patients will receive spinal anesthesia (using 2.5 mL of hyperbaric bupivacaine 0.5%) with bilateral transversalis fascia plane (TFP) block (using 20 mL of bupivacaine 0.25%) at the end of surgery.

DRUGIntrathecal dexmedetomidine

Patients will receive spinal anesthesia (using 2.5 mL of hyperbaric bupivacaine 0.5%) + (5 µg intrathecal dexmedetomidine diluted in 0.5ml saline) with a sham block at the end of surgery.


Locations(1)

Tanta University

Tanta, El-Gharbia, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07170267


Related Trials